These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35383042)

  • 21. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer.
    Shapiro LC; Thakkar A; Campbell ST; Forest SK; Pradhan K; Gonzalez-Lugo JD; Quinn R; Bhagat TD; Choudhary GS; McCort M; Sica RA; Goldfinger M; Goel S; Anampa JD; Levitz D; Fromowitz A; Shah AP; Sklow C; Alfieri G; Racine A; Wolgast L; Greenberger L; Verma A; Halmos B
    Cancer Cell; 2022 Jan; 40(1):3-5. PubMed ID: 34838186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign.
    Mattiuzzi C; Lippi G
    Eur J Public Health; 2022 Apr; 32(2):328-330. PubMed ID: 34978571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
    Keskin AU; Bolukcu S; Ciragil P; Topkaya AE
    J Med Virol; 2022 Jan; 94(1):39-41. PubMed ID: 34536028
    [No Abstract]   [Full Text] [Related]  

  • 24. Humoral response to vaccination against SARS-CoV-2 in patients undergoing dialysis.
    Lee YJ; Park BS; Heo CM; Park S; Yu S; Kim YW
    Medicine (Baltimore); 2022 Dec; 101(50):e32152. PubMed ID: 36550899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience.
    Yigit M; Ozkaya-Parlakay A; Cosgun Y; Ince YE; Bulut YE; Senel E
    J Med Virol; 2022 Jan; 94(1):287-290. PubMed ID: 34487373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
    Albach FN; Burmester GR; Biesen R
    Ann Rheum Dis; 2021 Oct; 80(10):1361-1362. PubMed ID: 34167947
    [No Abstract]   [Full Text] [Related]  

  • 27. Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir.
    Chen PC; Huang CC; Fu CM; Chang YC; Wu PJ; Lee WC; Lee CT; Tsai KF
    Viruses; 2023 Feb; 15(2):. PubMed ID: 36851757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
    Widge AT; Rouphael NG; Jackson LA; Anderson EJ; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Buchanan W; Luke CJ; Ledgerwood JE; Mascola JR; Graham BS; Beigel JH;
    N Engl J Med; 2021 Jan; 384(1):80-82. PubMed ID: 33270381
    [No Abstract]   [Full Text] [Related]  

  • 29. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis.
    Taheri S
    Int Urol Nephrol; 2023 Apr; 55(4):791-802. PubMed ID: 36723829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
    Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
    Front Immunol; 2021; 12():704773. PubMed ID: 34220867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
    Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
    Front Immunol; 2022; 13():940562. PubMed ID: 36091023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humoral response to SARS-CoV-2 after vaccination and booster effect in patients undergoing dialysis.
    Hernández-Porto M; García S; Delgado T; Rodriguez Y; Aguirre-Jaime A; Campos S; Hernández C; Lorenzo C; Lecuona M
    Int J Infect Dis; 2022 Sep; 122():327-331. PubMed ID: 35671949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do health-care workers need a COVID-19 vaccine booster?
    Cirillo N
    Lancet Infect Dis; 2022 Jan; 22(1):20. PubMed ID: 34953546
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
    Grenfell RFQ; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; Lourenço AJ; Martins-Filho OA; de Oliveira JG; Teixeira-Carvalho A; Campos GRF; Nogueira ML; Alves PA; Fernandes GR; Castilho LR; Lima TM; de Abreu DPB; Alvim RGF; Silva TBS; Jeremias WJ; Otta DA; Campi-Azevedo AC;
    Front Immunol; 2022; 13():918896. PubMed ID: 35757764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine.
    Liao Y; Zhang Y; Zhao H; Pu J; Zhao Z; Li D; Fan S; Yu L; Xu X; Wang L; Jiang G; Liu L; Li Q
    Emerg Microbes Infect; 2021 Dec; 10(1):1112-1115. PubMed ID: 34057040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral response to heterologous prime-booster vaccination in heart transplant recipients aged 18-70 years primed with a viral vector SARS-CoV-2 vaccine.
    Tanner R; Starr N; Perez-Garcia CN; Chan G; Dempsey E; Heffernan E; Lynch B; Hannan MM; Joyce E
    Transpl Infect Dis; 2022 Dec; 24(6):e13935. PubMed ID: 35980217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies and safety considerations of booster vaccination in COVID-19.
    Meng H; Mao J; Ye Q
    Bosn J Basic Med Sci; 2022 Jun; 22(3):366-373. PubMed ID: 35366790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis.
    Manley HJ; Li NC; Aweh GN; Hsu CM; Weiner DE; Miskulin D; Harford AM; Johnson D; Lacson E
    Am J Kidney Dis; 2023 Apr; 81(4):406-415. PubMed ID: 36462570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.